Juvenile Idiopathic Arthritis
The investigators sought to evaluate the time patients were in remission after discontinuing biologic therapy for the treatment of JIA.
The FDA has approved the subcutaneous formulation of Actemra for the treatment of active polyarticular juvenile idiopathic arthritis.
Baseline depressive symptoms were associated with pain and disability in adolescents with juvenile idiopathic arthritis.
Researchers evaluated the safety and efficacy of adalimumab and infliximab in the treatment of juvenile idiopathic arthritis-associated uveitis in patients treated for at least 2 years.
Investigators aimed to examine the use of treatment targets in juvenile idiopathic arthritis in terms of joint limitations, functional ability, psychosocial health, and pain levels.
The SHARE initiative has provided recommendations for the diagnosis and treatment of juvenile idiopathic arthritis-associated uveitis.
Clinical Features Identified in Enthesitis-Related Juvenile Idiopathic Arthritis, Juvenile SpondyloarthritisApril 20, 2018
Results confirm that juvenile spondyloarthritis is characterized by its peripheral pattern at disease onset, with peripheral arthritis and enthesitis.
The Epstein-Barr virus EBNA2 protein and many coclustering human transcription factors occupied nearly half of SLE risk loci.
Abnormal ultrasound findings were common in patients with juvenile idiopathic arthritis with clinically inactive disease.
Researchers sought to determine the predictors of disease flare after anti-TNF therapy discontinuation in children with polyarticular forms of juvenile idiopathic arthritis with sustained clinically inactive disease.
High neutrophil counts decreased after initiation of recombinant interleukin-1 receptor agonist therapy in systemic-onset juvenile idiopathic arthritis.
Children with juvenile idiopathic arthritis, pediatric inflammatory bowel disease, and pediatric plaque psoriasis had an increased incidence of childhood malignancies, regardless of TNFi exposure.
Abnormality on an ultrasound examination significantly increased the risk for flare in patients with juvenile idiopathic arthritis.
The goal of consensus treatment plans is to drive a cycle of innovation and replacement that allows the addition of new treatments and the removal of unused or ineffective strategies.
Autoantibodies that recognize cytosolic 5′-nucleotidase 1A were detected in about 25% of patients with juvenile myositis and juvenile idiopathic arthritis.
Treatment response was most significant in patients taking either tocilizumab or an interleukin-1 inhibitor.
Adalimumab was well tolerated and associated with persistent uveitis improvement in most cases.
An increase in disease activity 6 weeks postpartum suggests the need for tight follow-up of women with juvenile idiopathic arthritis.
Chronic inflammatory rheumatologic diseases benefit from early anti-inflammatory treatment; however, interdisciplinary approaches may be necessary for identifying and managing noninflammatory joint pain.
The objective of this study is to determine whether the JADAS or cJADAS would accurately predict patients with JIA in need of treatment escalation to anti-TNF after starting MTX.
Psychoeducational treatments can aid in the transition to adult care, but this is often lacking for teens due to access issues.
Real-world data indicate that although most patients with systemic lupus erythematosus or connective tissue diseases have successful pregnancies, more adverse pregnancy outcomes occur.
Technological advances may assist children and adolescents with JIA, who are both more forgetful and more resistant to therapy.
Golimumab use in children with active polyarticular-course JIA resulted in rapid, clinically meaningful improvements.
Ongoing inflammation related to JIA may put first-time mothers at risk for complications.
These guidelines address the use of antirheumatic drugs for adults with RA, SpA, JIA, and SLE undergoing THA or TKA.
When combined with ultrasound examination, ANG-2 can help lead to the appropriate therapy for JIA.
Clinicians should consider the risk/benefit of prescribing TNFIs to children with idiopathic arthritis.
In children with active juvenile idiopathic arthritis, the treatment combination controls eye inflammation.
Tocilizumab therapy showed rapid improvement in ocular parameters for uveitis in juvenile idiopathic arthritis patients.
Rheumatology Advisor Articles
- Alternative Measurement of Psoriasis Severity Effective in CZP-Treated Psoriatic Arthritis
- Incident Gout Risk, Serum Urate, and Comorbidities: What Are the Links?
- Addressing Psychiatric Comorbidities in Inflammatory Rheumatic Diseases
- Clinician Roundtable: Improving Quality of Life in Systemic Lupus Erythematosus
- Incidence of Clinically Significant GI Events in NSAID-Treated Arthritis
- EULAR Releases Recommendations for Pain Management in OA, Inflammatory Arthritis
- Risk of Developing Herpes Zoster Increased in Rheumatoid Arthritis
- Supervised, Intense Exercise Improves Physical Fitness in Older Adults With RA
- Risks Associated With Co-Administration of Aspirin and Other NSAIDs
- The Dorsal 4-Finger Technique: A New Method to Examine Joints in Rheumatoid Arthritis
- Gout, Urate-Lowering Therapy Not Associated With Risk for Fragility Fracture
- Does Exposure to Passive Smoke Increase Rheumatoid Arthritis Risk?
- Pegloticase Retreatment Effective for Gout After Gap in Therapy
- Tofacitinib Reduces MRI Inflammation, May Improve Outcomes in Ankylosing Spondylitis
- Associations Between Site-Specific BMD, Anthropometric, Glucose Homeostasis Traits